Skip to content

Released Mar 12, 2015, after the close

10-K filed Mar 12, 2015, 71 days after period end · 0001047469-15-002070

Q4 2014 · 10-K
Revenue—
Net Income-$6.23MN/M vs Q4 2013N/M vs Q3 2014
EPS Diluted-$0.30N/M vs Q4 2013N/M vs Q3 2014
Operating Incomederived-$5,943,000N/M
Operating Cash Flowderived-$6,154,000N/M
Free Cash Flowderived-$6,425,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2014Q4 2013Q4 2012
Revenue—$0.00$643.00K
Net Income-$6.23M-$5.74M-$4.16M
EPS Diluted-$0.30-$0.29-$3.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR